MetaCap

Novo Nordisk A/S (NVO) vs Vertex Pharmaceuticals (VRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Vertex Pharmaceuticals (VRTX) has outperformed Novo Nordisk A/S (NVO) over the past year, gaining 20.7% versus a loss of 20.6%. Over five years, VRTX leads with a +180.5% price change compared with -30.1% for NVO. Novo Nordisk A/S is the larger company by market cap ($166.69 billion vs $130.58 billion), about 1.3 times the size.

On valuation, Novo Nordisk A/S trades at a lower forward P/E (10.8x vs 25.9x for Vertex Pharmaceuticals). Novo Nordisk A/S pays a dividend yielding 30.94%, while Vertex Pharmaceuticals does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NVO-20.60%VRTX+20.68%
+37%+4%-29%
Nov 21, 20251 yearNov 20, 2026
NVO-33.57%VRTX+181.62%
+218%+84%-49%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NVO versus VRTX key metrics
MetricNVOVRTX
Share price$37.82$515.02
Market cap$166.69B$130.58B
1-day change-2.70%-1.08%
YTD return-25.67%+13.60%
1-year return-20.60%+20.68%
5-year return-30.07%+180.53%
P/E ratio (TTM)9.5533.14
Forward P/E10.7725.86
EPS (TTM)$3.96$15.54
Dividend yield30.94%0.00%
Annual dividend$11.70$0.00
Revenue (latest FY)—$12.00B
Revenue growth (YoY)—+8.90%
Net income (latest FY)—$3.95B
Gross margin—86.24%
Operating margin—34.77%
Net margin—32.94%
52-week high$64.16$568.67
52-week low$35.12$412.27
Distance from 52-week high-41.05%-9.43%
Analyst consensusholdbuy
Avg. price target upside+20.28%+15.60%
Average volume12.59M1.25M
Shares outstanding3.33B253.54M
Employees68,7946,400
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VRTX has outperformed NVO by 41.3 percentage points over the past year.
  • Vertex Pharmaceuticals trades at a higher earnings multiple (33.1x vs 9.6x trailing P/E).
  • Novo Nordisk A/S offers a meaningfully higher dividend yield (30.94% vs 0.00%).

About Novo Nordisk A/S

NVO stock →

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 68,794 employees

About Vertex Pharmaceuticals

VRTX stock →

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees

NVO vs VRTX FAQ

Which is bigger, Novo Nordisk A/S or Vertex Pharmaceuticals?

Novo Nordisk A/S (NVO) is larger, with a market capitalization of $166.69B compared with $130.58B for Vertex Pharmaceuticals (VRTX).

Which stock has performed better over the past year, NVO or VRTX?

VRTX returned +20.68% over the past 12 months, compared with -20.60% for NVO (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, NVO or VRTX?

NVO has the lower trailing P/E at 9.6, versus 33.1 for VRTX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Novo Nordisk A/S or Vertex Pharmaceuticals?

Novo Nordisk A/S pays a dividend yielding 30.94%, while Vertex Pharmaceuticals does not currently pay a regular dividend.

Are Novo Nordisk A/S and Vertex Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons